Stifel Upgrades Alkermes
Taking the first step to start addiction treatment is an uphill battle, but what can prove to be harder is keeping on a ...
Zacks.com on MSN13d
Alkermes' Q3 Earnings & Revenues Fall Shy of Estimates, Stock DownAlkermes plc ALKS reported adjusted earnings from continuing operations of 73 cents per share for third-quarter 2024, which ...
Among the posters, Alkermes presented results from a real-world, retrospective study of healthcare resource utilization (HCRU) and treatment patterns in patients with schizophrenia and patients with ...
Alkermes (NASDAQ:ALKS – Free Report) had its price target lowered by Cantor Fitzgerald from $48.00 to $43.00 in a research ...
Alkermes plc (NASDAQ:ALKS), a biopharmaceutical company specializing in central nervous system (CNS) diseases, is undergoing a significant transformation. The company is shifting from a royalty ...
Robert W. Baird analyst Joel Beatty maintained a Buy rating on Alkermes (ALKS – Research Report) yesterday and set a price target of ...
Alkermes (NASDAQ:ALKS – Get Free Report) had its target price dropped by equities researchers at The Goldman Sachs Group from ...
Third Quarter 2024 Results Key Financial Results Revenue: US$378.1m (flat on 3Q 2023).
In a report released yesterday, Charles Duncan from Cantor Fitzgerald initiated coverage with a Buy rating on Alkermes (ALKS – Research ...
Note 1. Under SAR 3, the holdings of and acquisitions by persons acting in concert must be aggregated and treated as a holding of or acquisition by one person. SAR 8(b) requires persons who must ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback